Smoldering Multiple Myeloma

iStopMM team members Thorir Einarsson Long, Jon Thorir Oskarsson, and Sæmundur Rognvaldsson are 2023 ASH Abstract Achievement AwardeesSTUDIO CITY, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation’s Black Swan Research Initiative® (BSRI) proudly showcased four oral and two poster abstracts from the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA which took place from December 9-12, 2023. This year, the iStopMM oral and poster presentations investigated: The early benefits and psychological effects of screening for MGUS, based on the results of the iStopMM study. (Abstract #214: The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the iStopMM Study)The relationship of MGUS and thrombosis in a population-based screened cohort of individuals with MGUS; evaluating the benefits and harms of MGUS screening. (Abstract #216: Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombosis Events: Results from iStopMM, a Population-Based Screening Study in Iceland)The association between free-light chain ratio and the presence of clonal plasma cells in the bone marrow of individuals with light-chain monoclonal gammopathies as well as the risk of progression. (Abstract #530: Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio)Revising the definition of free light chains in serum and light chain MGUS through the results of a large population-based study. (Abstract #535: Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the iStopMM Study)Identifying potential risk factors of SMM by analyzing the association of baseline characteristics, body mass index, smoking, alcohol consumption, prior diagnoses of autoimmune diseases and prior chronic infections and SMM in the screened iStopMM study cohort. (Abstract #3397: Risk Factors of Smoldering Multiple Myeloma: Results from the Screened iStopMM Study)If a SARS-CoV-2 infection has an impact on the risk of progression from MGUS to MM through a population-based iStopMM screening study. (Abstract #4766: Sars-CoV-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based iStopMM Screening Study) A Media Snippet accompanying this announcement is available by clicking on this link. The IMF and BSRI are also proud to announce that three iStopMM Project team members are recipients of the prestigious ASH Abstract Achievement Award this year: Thorir Einarsson Long for Abstract #535: Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the iStopMM StudyJon Thorir Oskarsson for Abstract #530: Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain RatioSæmundur Rognvaldsson for Abstract #216: Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombosis Events: Results from iStopMM, a Population-Based Screening Study in Iceland Launched in 2016, the iStopMM Project is the first large-scale screening study in the field of myeloma — an ambitious research project supported by the IMF and led by principal investigator Prof. Kristinsson. The study also includes a randomized trial of follow-up strategies. In a recent Ask Dr. Durie video, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie discusses the iStopMM Project’s purpose in doing the large-scale screening study and the advantages that come with early screening. For more in-depth insights from Dr. Durie on the latest myeloma research from ASH 2023, the IMF invites you to watch the replays of the IMWG Conference Series 2023: Making Sense of Treatment and Top Myeloma Research Presented at ASH 2023 from a Patient Perspective. To learn more about the 2023 ASH Abstracts, visit hematology.org. You may also access the complete list of 2023 ASH Abstract Achievement Awardees on the ASH website. ABOUT THE BLACK SWAN RESEARCH INITIATIVE®The International Myeloma Foundation (IMF) has banded together the world’s brightest minds in research, oncology, and health studies to form the IMF’s Black Swan Research Initiative® (BSRI) – a leading-edge project that pits our scientists and leaders on the frontlines against myeloma. The IMF’s BSRI was established in 2012, following a scientific brainstorming meeting linked to the International Myeloma Working Group (IMWG) Summit in Amsterdam. Together, the IMF and BSRI’s mission is to find the first definitive cure for myeloma and to help bridge the gap from long-term remission to cure. Led by an international consortium of myeloma experts, BSRI is bridging the gap from long-term remission to cure by sharing collective data and tracking myeloma through multiple, simultaneous drug trials and therapies to determine which work best. ABOUT THE ISTOPMM PROJECTLaunched in 2016, the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project is the first population-based screening study for monoclonal gammopathy of undetermined significance (MGUS), with Dr. Sigurdur Y. Kristinsson of the University of Iceland as principal investigator. The study also includes a randomized trial of follow-up strategies. The iStopMM Project is one of several global research projects supported by the IMF Black Swan Research Initiative® (BSRI) which is committed to finding a cure for myeloma. ABOUT THE INTERNATIONAL MYELOMA FOUNDATIONFounded in 1990, the International Myeloma Foundation (IMF) is the first and largest global foundation focusing specifically on multiple myeloma. The Foundation's reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy. The IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned InfoLine, and in 2001, established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. In 2012, the IMF launched the Black Swan Research Initiative®, a groundbreaking research project aimed at curing myeloma. The IMF can be reached at (800) 452-CURE (2873). The global website is www.myeloma.org. Follow the IMF on: Twitter: @IMFmyeloma Instagram: @imfmyelomaFacebook: @myelomaLinkedIn: International Myeloma Foundation Media Contacts: Peter Anton Panton@myeloma.org Jason LondonJlondon@myeloma.org

Toronto, Ontario--(News - December 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (ASH) annual meeting in San Diego this week. The Company will present the repeatability analytical validation data of its lead product TeloViewSMM, while interacting with a global group of physicians and researchers and educating on the importance of telomere-based assessment of Smoldering Multiple Myeloma (SMM). The 2023 ASH meeting taking place between December 9-12, 2023 in San Diego, USA, is an important milestone for Telo Genomics, as the Company offers it's TeloViewSMM assay to clinicians for the first time as a commercially available product. TeloViewSMM is a non-invasive liquid biopsy, featuring 3D telomere analysis, that utilizes the TeloView® software platform to quantify genomic instability and transformation risk. The assay is a laboratory developed test, conducted at Telo's high-complexity ISO 15189 certified lab in Toronto. Telo Genomics CEO Kris Weinberg commented on the excitement within the company surrounding ASH attendance and lauded his team for their efforts "Through a lot of hard work and creative energy, we are bringing TeloViewSMM to the audience at ASH. Our entire team is dedicated to improving disease management and outcomes for patients diagnosed with Smoldering Multiple Myeloma." About the TeloView® Platform TeloViewSMM is the first marketed product/use case in the TeloView® platform portfolio. As the core enabling technology of the portfolio, TeloView uses quantitative analysis of 3D telomeres in combination with molecular biology and artificial intelligence to recognize disease associated genetic instability. The novel biomarkers enabled by the TeloView platform quantify the risk of cancer progression beyond standard phenotypic measures and are additive to standard molecular analysis. The utility of TeloView as both a research and clinical tool has been substantiated in over 160 peer reviewed publications and 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. About TeloViewSMM TeloViewSMM is a first-in-class telomere-based molecular tool that integrates proprietary quantitative analytics and artificial intelligence to evaluate the 3D organization of telomeres as a predictor of disease transformation in Smoldering Multiple Myeloma (SMM). The proprietary assay (and associated platform technology) quantifies risk of transformation/progression beyond standard phenotypic measures. Over 200,000 patients in the United States are currently living with smoldering Multiple Myeloma. The TeloViewSMM assay has a potential total addressable market of over 500,000 tests per year. About Telo Genomics Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and predictive/prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TeloView-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit . For further information, please contact: Kris Weinberg, CEO 678-429-5582 kris.weinberg@telodx.com MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7 Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit

SMART Observational Study a Critical Step Toward Full Platform Availability Toronto, Ontario--(News - November 16, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, is excited to announce the initiation of their Physician Experience Program - SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation). SMART is an observational study intended for cancer treating physicians and their staff in the US to gain experience ordering and utilizing the TeloViewSMM assay. With this launch, participating physicians and their care teams have access to novel molecular information to assist in selecting management strategies for their patients diagnosed with Smoldering Multiple Myeloma - a precursor to a painful and deadly form of cancer - active multiple myeloma ("MM"). TeloViewSMM is a non-invasive liquid biopsy, using 3-dimensional telomere analysis, that utilizes the TeloView® software platform to quantify genomic instability and transformation risk. The assay is conducted at Telo's high-complexity ISO-approved lab in Toronto. TeloViewSMM uses 3D structural assessment to identify patients with high risk of transformation to full stage MM who are likely to benefit from earlier treatment intervention and achieve better clinical outcomes. Just as important, TeloViewSMM can discriminate or rule out the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. These patients can receive a higher quality of life without costly, debilitating chemotherapy before it is necessary, and can be regularly monitored using Telo's test. Commenting on the launch of SMART, Richard A. Bender MD, FACP said, "I'm encouraged that new biomarkers and novel approaches are being pursued in this patient population. Having access to the TeloViewSMM assay promises to improve management of my patients with Smoldering Multiple Myeloma." Dr. Bender, Chairman of Telo's Clinical Advisory Board, went on to say, "My practice and others that enroll in SMART will offer a better-informed assessment of transformation risk while helping Telo Genomics introduce the TeloViewSMM assay to a wider physician user base." About SMART The SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation) observational protocol (TG-SMM-001) is an IRB-approved study initiated by Telo Genomics in November of 2023 to assess clinical and laboratory dynamics around the use of TeloViewSMM. Evaluation and approval of the protocol were conducted by Advarra, an IRB whose membership complies with the requirements defined in Health Canada regulations, ICH GCP guidelines, FDA regulations at 21 CFR part 56, and HHS regulations at 45 CFR part 46. The IRB carries out its functions in accordance with FDA regulations at 21 CFR parts 50, 56, 312, and 812; HHS regulations at 45 CFR part 46, subparts A-E; good clinical practices; Health Canada regulations; and the Tri-Council Policy Statement. Advarra IRB is registered with OHRP and FDA under IRB #00000971. About TeloViewSMM TeloViewSMM is a first-in-class telomere-based molecular tool that integrates proprietary quantitative analytics and artificial intelligence to evaluate the 3D organization of telomeres as a predictor of disease transformation in Smoldering Multiple Myeloma (SMM). The proprietary assay (and associated platform technology) quantifies risk of transformation/progression beyond standard phenotypic measures. Over 200,000 patients in the United States are currently living with smoldering Multiple Myeloma. The TeloView-SMM assay has a potential total addressable market of over 500,000 tests per year. About Telo Genomics Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and predictive/prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TeloView-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit . For further information, please contact: Kris Weinberg, CEO 678-429-5582 kris.weinberg@telodx.com MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7 Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit